Navigation Links
Pharmatech Oncology Announces Completion of SBIR Grant Research
Date:10/20/2011

DENVER, Oct. 20, 2011 /PRNewswire/ -- Pharmatech Oncology announces completion of a phase I Small Business Innovative Research (SBIR) grant project, funded by the National Cancer Institute (NCI). 

The SBIR grant project evaluated Pharmatech Oncology's innovative enrollment model called Just-in-Time (JIT) to enroll cancer patients into clinical trials.  The JIT model is prioritized around detection of patients with qualifying diagnoses across many research practices. Patients who meet study entry criteria and have interest in receiving the investigational treatment are enrolled into the trial within two weeks through rapid regulatory activation of their care center as a study site.  JIT is a patient-focused approach designed to align clinical research with cancer patient care as it is currently delivered in the US.

The SBIR project evaluated the feasibility and efficiency of JIT in five separate studies, comparing the research performance of JIT-initiated sites to traditionally managed sites in retrospective analyses.  JIT demonstrated advantages in several important areas:

  • Higher patient enrollment rates (3.1x greater at six months)
  • Fewer non-enrolling sites (77% reduction)
  • Reduced time to first patient enrolled  (79-95% fewer days)
  • Lower administrative cost per site
  • No reduction of patient safety or data quality

"The SBIR phase I results have significant implications for the commercial development of the JIT model," remarked Dr. Matthew Wiener, Pharmatech founder.  "The positive impact on the clinical trials we've evaluated has been profound. With this essential validation of the methodology we are beginning to see awareness and adaptation of JIT increase among study centers and sponsors, which is critical to the growth of JIT as a commercial research solution." Pharmatech Oncology has submitted an application for a new SBIR grant to fund a phase II program with the aim to develop the JIT model further toward such commercialization.  Dr. Wiener comments, "Our vision for JIT is that any cancer patient and oncologist in any research-capable practice should have access to all appropriate treatment options, including clinical trials."

About Pharmatech Oncology, Inc.:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting the inclusion of clinical trials in the spectrum of patient treatment options.


For more information about Pharmatech, please visit www.pharmatechoncology.com.

The project described was supported by Award Number R43CA144362 from the National Cancer institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.


'/>"/>
SOURCE Pharmatech Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Congratulates the 2010 Nobel Laureates in Chemistry
2. Quest PharmaTech Announces Formation of Clinical Advisory Panel
3. Pharmatech Oncology to Present at 46th Annual DIA Meeting
4. Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial
5. WuXi PharmaTech Files 2009 Annual Report on Form 20-F
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
7. WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing
8. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
9. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
10. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
11. WuXi PharmaTech Announces Second-Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis since ... ligament in her left knee. Lady’s owner Hannah sought the help of Dr Jeff ... surgeon, to repair her cruciate ligament and help with the pain of Lady’s arthritis. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for a range ... by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented method ... , The novel method, developed by WPI faculty members Raymond Page, PhD, professor ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, ... executives and entrepreneurs, held The Future of San Diego Life Science event at the ... life science community attended the event with speakers Dr. Rich Heyman, former CEO of ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across the ... Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations across ... down 21 percent in South Texas in the last four years alone. , There is ...
Breaking Biology Technology:
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
(Date:3/9/2016)... -- Nigeria . Recently, the ... public service employees either did not exist with their ...    --> Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> DERMALOG, the biometrics innovation ...
Breaking Biology News(10 mins):